Literature DB >> 11300875

Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity.

F Clerici1, D Pocar, M Guido, A Loche, V Perlini, M Brufani.   

Abstract

Recently a series of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives bearing different substituents were synthesized and screened pharmacologically in order to evaluate their central nervous system activity. The purpose of this study was to evaluate the effects of the title compounds on CNS activity by varying the substituents in the thiadiazole moiety. It was found that some of these compounds possess marked antidepressant and anxiolytic properties comparable in efficiency to the reference drugs Imipramine and Diazepam. The most potent compound 3k was further investigated to complete its pharmacological profile with respect to undesired side effects. Behavioral results showed that 3k is a very promising compound, characterized by a mixed antidepressant-anxiolytic activity accompanied by a therapeutic dose range that is essentially 2 orders of magnitude less than that at which side effects such as sedation and amnesia are evident.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300875     DOI: 10.1021/jm001027w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Pseudomonas aeruginosa porphobilinogen synthase assembly state regulators: hit discovery and initial SAR studies.

Authors:  Allen B Reitz; Ursula D Ramirez; Linda Stith; Yanming Du; Garry R Smith; Eileen K Jaffe
Journal:  ARKIVOC       Date:  2010-06       Impact factor: 1.140

2.  Discovery of Fused Triazolo-thiadiazoles as Inhibitors of TNF-alpha: Pharmacophore Hybridization for Treatment of Neuropathic Pain.

Authors:  Monika Sharma; Vanamala Deekshith; Arvind Semwal; Dharmarajan Sriram; Perumal Yogeeswari
Journal:  Pain Ther       Date:  2012-09-11

3.  Facile, efficient and one-pot access to diverse new functionalized aminoalkyl and amidoalkyl naphthol scaffolds via green multicomponent reaction using triethylammonium hydrogen sulfate ([Et3NH][HSO4]) as an acidic ionic liquid under solvent-free conditions.

Authors:  Elahe Hadadianpour; Behjat Pouramiri
Journal:  Mol Divers       Date:  2019-04-05       Impact factor: 2.943

4.  Synthesis and Antimicrobial Activity Screening of Piperazines Bearing N,N'-Bis(1,3,4-thiadiazole) Moiety as Probable Enoyl-ACP Reductase Inhibitors.

Authors:  Alaa Z Omar; Najla A Alshaye; Tawfik M Mosa; Samir K El-Sadany; Ezzat A Hamed; Mohamed A El-Atawy
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

5.  N-(5-Methyl-sulfanyl-1,3,4-thia-diazol-2-yl)acetamide.

Authors:  Guo-Ying Zhang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-08-12

6.  Synthesis and antimicrobial activity of some new 1,3,4-thiadiazole and 1,2,4-triazole compounds having a D,L-methionine moiety.

Authors:  Otilia Pintilie; Lenuta Profire; Valeriu Sunel; Marcel Popa; Aurel Pui
Journal:  Molecules       Date:  2007-01-29       Impact factor: 4.411

7.  2,2'-Bi-1,3,4-thia-diazole-5,5'-diamine tetra-hydrate.

Authors:  Chaveng Pakawatchai; Saowanit Saithong
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-08-04

8.  Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review.

Authors:  Nadeem Siddiqui; Sandhya Bawa; Ruhi Ali; Obaid Afzal; M Jawaid Akhtar; Bishmillah Azad; Rajiv Kumar
Journal:  J Pharm Bioallied Sci       Date:  2011-04

9.  Synthesis and evaluation of substituted diphenyl-1,3,4-oxadiazole derivatives for central nervous system depressant activity.

Authors:  Poonam Singh; Pramod Kumar Sharma; Jitendra Kumar Sharma; Anshu Upadhyay; Nitin Kumar
Journal:  Org Med Chem Lett       Date:  2012-03-01

10.  N-(5-Benzyl-sulfanyl-1,3,4-thia-diazol-2-yl)-2-(piperidin-1-yl)acetamide.

Authors:  D S Ismailova; R Ya Okmanov; A A Ziyaev; Kh M Shakhidoyatov; B Tashkhodjaev
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.